重组人干扰素α-2b联合阿德福韦酯治疗乙肝肝硬化的效果及其对AQP8和AQP9蛋白水平的影响  

Effect of recombinant human interferonα-2b combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis and its influences on the levels of AQP8 and AQP9 proteins

作　　者：杜菽[1] 郭呈芳[1] 邹慧娟[1] 薄宇清 王利红[1] DU Shu;GUO Chengfang;ZOU Huijuan;BO Yuqing;WANG Lihong(Infectious Diseases Department,Xinxiang Central Hospital,Xinxiang 453000,China)

机构地区：[1]新乡市中心医院感染性疾病科,河南新乡453000

出　　处：《临床医学研究与实践》2020年第35期76-77,83,共3页Clinical Research and Practice

摘　　要：目的研究重组人干扰素α-2b联合阿德福韦酯治疗乙肝肝硬化的效果及其对AQP8和AQP9蛋白水平的影响。方法选取我院2018年1月至2020年1月收治的122例乙肝肝硬化患者为研究对象,采用随机数字法将其分为对照组和观察组,每组61例。对照组给予阿德福韦酯治疗,观察组在此基础上联合重组人干扰素α-2b治疗。比较两组患者的治疗效果。结果治疗后,观察组的TBIL、AST、ALT水平均明显低于对照组(P<0.05);观察组的HBV-DNA转阴率明显高于对照组(P<0.05);治疗后,观察组AQP8、AQP9水平明显高于对照组(P<0.05)。结论重组人干扰素α-2b联合阿德福韦酯治疗乙肝肝硬化的临床效果显著,可提高AQP8和AQP9蛋白的表达水平,抑制HBV的复制,促进肝脏功能恢复,且安全性较高,值得在临床推广。Objective To study the effect of recombinant human interferonα-2b combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis and its influences on the levels of AQP8 and AQP9 proteins.Methods A total of 122 patients with hepatitis B cirrhosis admitted in our hospital from January 2018 to January 2020 were selected as study objects and divided into control group and observation group by random number method,with 61 cases in each group.The control group was treated with adefovir dipivoxil,and the observation group was treated with recombinant human interferonα-2B on this basis.The therapeutic effects of the two groups were compared.Results After treatment,TBIL,AST and ALT levels in the observation group were significantly lower than those in the control group(P<0.05);the negative conversion rate of HBV-DNA in the observation group was significantly higher than that in the control group(P<0.05);after treatment,AQP8 and AQP9 levels in the observation group were significantly higher than those in the control group(P<0.05).Conclusion Recombinant human interferonα-2b combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis has a significant clinical effect,it can improve the expression levels of AQP8 and AQP9 proteins,inhibit HBV replication,promote the recovery of liver function,with higher safety,which is worthy of clinical promotion.

关 键 词：重组人干扰素Α-2B 阿德福韦酯 乙肝肝硬化 水通道蛋白 

分 类 号：R512.62[医药卫生—内科学]